Comorbidities among COVID-19 patients: based on studies published before 25 February 2020
Citation: Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International Journal of Infectious Diseases 2020; 94: 91-95
What is this? The symptoms of COVID-19 range from those that might not be noticeable to severe life-threatening illness. The presence of certain comorbidities may represent potential risk factors for poorer outcomes.
In this rapid review, the authors searched for studies which described the epidemiological, clinical features of COVID-19, and the prevalence of chronic diseases in infected patients. They restricted their search to articles published from January 2019 to February 2020, and did the search on 25 February 2020. They included 7 studies, including 1576 patients with laboratory-confirmed COVID-19 from hospitals in China in their meta-analysis.
What was found: At the time of this review, available research showed that the most prevalent clinical symptom was fever, followed by cough, fatigue and dyspnea.
At the time of this review, available research showed that the most common comorbidities were hypertension, diabetes, cardiovascular disease and respiratory disease.
At the time of this review, available research showed that patients with severe COVID-19 illness were more than three times as likely to have cardiovascular disease, more than twice as likely to have hypertension and more than twice as likely to have respiratory disease, than patients with non-severe illness.
At the time of this review, the prevalence rates of these comorbidities in COVID-19 cases in other parts of the world was uncertain.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.